Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosi...

Full description

Bibliographic Details
Main Authors:	Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Journal of Clinical Medicine
Subjects:	adalimumab biosimilar GP2017 inflammatory bowel disease ulcerative colitis Crohn’s disease
Online Access:	https://www.mdpi.com/2077-0383/12/21/6839

Similar Items

Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
by: Giammarco Mocci, et al.
Published: (2022-07-01)

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
by: Giammarco Mocci, et al.
Published: (2023-10-01)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
by: Fang Wang, et al.
Published: (2023-10-01)

Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
by: Valeria Dipasquale, et al.
Published: (2024-02-01)

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
by: Vandana Midha, et al.
Published: (2018-01-01)

Prevalence and Clinical Impact of Immune-Mediated Inflammatory Diseases in Patients with Inflammatory Bowel Disease: Results from a Large Retrospective Observational Study
by: Marta Vernero, et al.
Published: (2024-02-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Adalimumab in Pediatric Inflammatory Bowel Disease
by: So Yoon Choi, et al.
Published: (2022-04-01)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
by: Trinidad Montero-Vilchez, et al.
Published: (2022-02-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease
by: Silvia Marquez-Megias, et al.
Published: (2021-08-01)

A Budget impact analysis of adalimumab biosimilar: the Italian context
by: Roberto Ravasio, et al.
Published: (2019-05-01)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01)

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
by: Sanjiv Kapoor, et al.
Published: (2019-06-01)

Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study
by: Wei-Chen Lin, et al.
Published: (2017-10-01)

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study
by: Hong Zhang, et al.
Published: (2021-04-01)

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
by: Stefan Schreiber, et al.
Published: (2020-06-01)

Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
by: Rianne Brouwer, et al.
Published: (2022-12-01)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
by: Roy M. Fleischmann, et al.
Published: (2018-08-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2020-12-01)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
by: Roy M. Fleischmann, et al.
Published: (2021-09-01)

A prospective, randomized, double-blind, comparative clinical study of efficacy and safety of a biosimilar adalimumab with innovator product in patients with active rheumatoid arthritis on a stable dose of methotrexate
by: Prasad Apsangikar, et al.
Published: (2018-01-01)

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
by: Ferdinando D’Amico, et al.
Published: (2023-10-01)

Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers
by: Eva Dokoupilová, et al.
Published: (2024-06-01)

Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease Posición conjunta de la Sociedad Española de Patología Digestiva y de la Sociedad Española de Farmacología sobre el tratamiento con biosimilares en la enfermedad inflamatoria intestinal
by: Federico Argüelles-Arias, et al.
Published: (2013-01-01)

A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
by: Hong Zhang, et al.
Published: (2021-03-01)

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries
by: Peter C. Taylor, et al.
Published: (2023-01-01)

Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn's Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study
by: Chen-Wang Chang, et al.
Published: (2014-10-01)

Diagnostic value of anti-GP2 antibodies determined in serum and coprofiltrates in children with inflammatory bowel disease
by: A. P. Toptygina, et al.
Published: (2020-08-01)

Navigating adalimumab biosimilars: an expert opinion
by: Vered Abitbol, et al.
Published: (2023-10-01)

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars
by: O. V. Knyazev, et al.
Published: (2021-02-01)

Adalimumab induced psoriasis during the treatment of inflammatory bowel disease – case report
by: Edyta Lelonek, et al.
Published: (2015-09-01)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
by: Glenn Harvin, et al.
Published: (2016-05-01)

Clinical features of active tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflammatory bowel disease
by: Jang Wook Lee, et al.
Published: (2016-04-01)

Are We Ready for Biosimilars in Gastroenterology?
by: Muhammad Ilham Abdul Hafidz, et al.
Published: (2017-12-01)

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey
by: Marta Vernero, et al.
Published: (2024-03-01)

Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease
by: Amedeo De Nicolò, et al.
Published: (2022-12-01)

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
by: William D. Renton, et al.
Published: (2019-10-01)

Biosimilar Interchangeability and Emerging Treatment Strategies for Inflammatory Bowel Diseases: A Commentary
by: Richard H. Parrish
Published: (2021-06-01)